Pharmaceuticals & Biotechnology Editor | 02/23/2012
Current estimates indicate that 40% of drugs on the market place and 90% of APIs in development are poorly soluble. David Elder, Externalisation Director for GlaxoSmithKline and Pharma IQ Advisory Board Member, joins Andrea Charles from Pharma IQ, to discuss the ever-increasing numbers of poorly soluble drugs coming to market and utilising in silico and computational modelling to better predict absorption of new chemical entities.
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
AI for Pharma & Healthcare
23 - 25 September, 2025
Amsterdam
Register Now |
View Agenda |
Learn More